Literature DB >> 3120516

Spectrophotometric monitoring of lipoxygenase and cyclooxygenase pathway activity using ionophore stimulated whole blood.

F J Sweeney1, J D Eskra, M J Ernest, T J Carty.   

Abstract

We have employed clotting human blood stimulated with ionophore to develop a system for measuring cyclooxygenase, 5-lipoxygenase, and 12-lipoxygenase pathway products released into the serum fraction. In a single chromatographic run, 5-HETE, 12-HETE, 12-OH-heptadecatrienoic acid (HHT), LTB4, 20-OH-LTB4, and 20-COOH-LTB4 are quantitated by UV monitoring after separation by HPLC. The kinetics of product formation/release of all fatty acid products into the serum show an apparent lag of approximately 2 min, after which time the amounts of HHT, 5-HETE, and LTB4, respectively, plateau at 10 min while 12-HETE increases over a 60 min period. The system is responsive to standard cyclooxygenase and lipoxygenase inhibitors, and is of value of evaluating prospective blockers of AA metabolism in a whole blood setting.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120516     DOI: 10.1007/bf01966526

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

1.  The metabolism of leukotrienes in blood plasma studied by high-performance liquid chromatography.

Authors:  M Köller; W Schönfeld; J Knöller; K D Bremm; W König; B Spur; A Crea; W Peters
Journal:  Biochim Biophys Acta       Date:  1985-01-09

2.  Development of a system for evaluating 5-lipoxygenase inhibitors using human whole blood.

Authors:  F J Sweeney; J D Eskra; T J Carty
Journal:  Prostaglandins Leukot Med       Date:  1987-06

3.  Radioimmunoassay of LTB4 and 6-trans LTB4: analytical and pharmacological characterisation of immunoreactive LTB4 in ionophore stimulated human blood.

Authors:  F Carey; R A Forder
Journal:  Prostaglandins Leukot Med       Date:  1986-04

4.  Leukotriene B4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells.

Authors:  P Gresele; J Arnout; M C Coene; H Deckmyn; J Vermylen
Journal:  Biochem Biophys Res Commun       Date:  1986-05-29       Impact factor: 3.575

5.  Solid-phase extraction and high-performance liquid chromatography analysis of lipoxygenase pathway products.

Authors:  J D Eskra; M J Pereira; M J Ernest
Journal:  Anal Biochem       Date:  1986-04       Impact factor: 3.365

6.  Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187.

Authors:  P Borgeat; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

7.  Piroxicam, a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition.

Authors:  T J Carty; J S Stevens; J G Lombardino; M J Parry; M J Randall
Journal:  Prostaglandins       Date:  1980-05

8.  Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets.

Authors:  M Hamberg; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

  8 in total
  4 in total

1.  Evaluation of Tenidap (CP-66,248) on human neutrophil arachidonic acid metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis.

Authors:  D M Smith; J A Johnson; R Loeser; R A Turner
Journal:  Agents Actions       Date:  1990-08

2.  Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam.

Authors:  T J Carty; A Marfat; P F Moore; F C Falkner; T M Twomey; A Weissman
Journal:  Agents Actions       Date:  1993-07

3.  Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production.

Authors:  J M Young; S Panah; C Satchawatcharaphong; P S Cheung
Journal:  Inflamm Res       Date:  1996-05       Impact factor: 4.575

4.  Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice.

Authors:  R J Griffiths; M A Smith; M L Roach; J L Stock; E J Stam; A J Milici; D N Scampoli; J D Eskra; R S Byrum; B H Koller; J D McNeish
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.